Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_assertion type Assertion NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_head.
- NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_assertion description "[Crizotinib, an oral ALK inhibitor, has proved to provide dramatic clinical benefit in patients with NSCLC harboring ALK rearrangements.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_provenance.
- NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_assertion evidence source_evidence_curated NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_provenance.
- NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_assertion SIO_000772 22920921 NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_provenance.
- NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_assertion wasDerivedFrom ctd_human-20150221 NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_provenance.
- NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_assertion wasGeneratedBy ECO_0000218 NP6718.RAbVH457b-LkpJWRMgTw7ueS7pj6MBG5QtMY95W0zUhuQ130_provenance.